BR112012008518A2 - derivado heterocíclico, e, composição farmacêutica - Google Patents

derivado heterocíclico, e, composição farmacêutica

Info

Publication number
BR112012008518A2
BR112012008518A2 BR112012008518A BR112012008518A BR112012008518A2 BR 112012008518 A2 BR112012008518 A2 BR 112012008518A2 BR 112012008518 A BR112012008518 A BR 112012008518A BR 112012008518 A BR112012008518 A BR 112012008518A BR 112012008518 A2 BR112012008518 A2 BR 112012008518A2
Authority
BR
Brazil
Prior art keywords
heterocyclic derivative
pharmaceutical composition
heterocyclic
present
derivative
Prior art date
Application number
BR112012008518A
Other languages
English (en)
Portuguese (pt)
Inventor
Fiona Jeremiah
John Kinnaird Ferguson Maclean
Paul David Ratcliffe
Thomas Rusell Clarkson
Original Assignee
Msd Oss Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Oss Bv filed Critical Msd Oss Bv
Publication of BR112012008518A2 publication Critical patent/BR112012008518A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112012008518A 2009-10-13 2010-10-11 derivado heterocíclico, e, composição farmacêutica BR112012008518A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25110109P 2009-10-13 2009-10-13
EP09172872 2009-10-13
PCT/EP2010/065160 WO2011045258A1 (en) 2009-10-13 2010-10-11 Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor

Publications (1)

Publication Number Publication Date
BR112012008518A2 true BR112012008518A2 (pt) 2016-04-05

Family

ID=42040651

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008518A BR112012008518A2 (pt) 2009-10-13 2010-10-11 derivado heterocíclico, e, composição farmacêutica

Country Status (12)

Country Link
US (1) US8841289B2 (https=)
EP (1) EP2488520B1 (https=)
JP (1) JP2013507417A (https=)
KR (1) KR20120100913A (https=)
CN (1) CN102666540A (https=)
AU (1) AU2010305825A1 (https=)
BR (1) BR112012008518A2 (https=)
CA (1) CA2776835A1 (https=)
IN (1) IN2012DN02968A (https=)
MX (1) MX2012004289A (https=)
RU (1) RU2012119488A (https=)
WO (1) WO2011045258A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336268B (es) 2011-07-29 2016-01-13 Toyama Chemical Co Ltd Compuesto de amidina o sal del mismo.
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
EP2852382A1 (en) * 2012-05-22 2015-04-01 King Abdullah University Of Science And Technology Combination comprising parthenolide for use in the treatment of alzheimer's disease and other neurodegenerative disorders
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
US9840491B2 (en) 2015-02-05 2017-12-12 Forma Therapeutics, Inc. Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253765A1 (en) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
US9938300B2 (en) 2015-02-05 2018-04-10 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN106146410B (zh) * 2015-04-03 2018-10-12 中南大学 6-氨基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
CN106279211B (zh) 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
CN107847494A (zh) 2015-06-10 2018-03-27 阿考温特科学股份有限公司 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
JP2018523707A (ja) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス,インコーポレーテッド ヘテロ芳香族nmda受容体モジュレーターおよびその使用
EP4006038A1 (en) 2015-12-09 2022-06-01 Cadent Therapeutics, Inc. Thienopyrimidinone nmda receptor modulators and uses thereof
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
BR112020026637A2 (pt) * 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
KR20210039368A (ko) 2018-07-26 2021-04-09 도메인 테라퓨틱스 치환된 퀴나졸리논 유도체 및 mGluR4의 양성 알로스테릭 조절인자로서의 이의 용도
AR115905A1 (es) 2018-08-03 2021-03-10 Cadent Therapeutics Inc 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda
WO2021198191A1 (en) 2020-03-30 2021-10-07 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
US20230150978A1 (en) 2020-03-30 2023-05-18 Enyo Pharma Quinazolinone derivatives and uses thereof for treating a cancer
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN112898290B (zh) * 2021-01-29 2022-08-05 中南大学 异噁唑甲酰胺基-4(3h)-喹唑啉酮衍生物及其合成方法和用途
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2025176185A1 (zh) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 一种braf抑制剂的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
CA2444598A1 (en) * 2001-04-20 2003-10-31 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of gsk-3
US7148236B2 (en) * 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
TW200536830A (en) * 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
CA2615577C (en) * 2005-07-26 2014-09-09 Sanofi-Aventis Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
CN101600698B (zh) 2006-09-11 2012-01-11 欧加农股份有限公司;药典有限责任公司 喹唑啉酮和异喹啉酮乙酰胺衍生物
MY148902A (en) * 2006-12-27 2013-06-14 Sanofi Aventis Substituted isoquinolines and their use as rho-kinase inhibitors
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−4−オン誘導体
EP2209783B8 (en) * 2007-11-14 2016-06-01 Saniona A/S Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use
CN101960691B (zh) 2008-02-29 2013-04-24 核心技术国际有限公司 电池组的充电装置和电池组的品质判断装置

Also Published As

Publication number Publication date
KR20120100913A (ko) 2012-09-12
IN2012DN02968A (https=) 2015-07-31
CN102666540A (zh) 2012-09-12
MX2012004289A (es) 2012-06-12
EP2488520A1 (en) 2012-08-22
RU2012119488A (ru) 2013-11-20
EP2488520B1 (en) 2015-09-02
CA2776835A1 (en) 2011-04-21
AU2010305825A1 (en) 2012-04-19
US20120208796A1 (en) 2012-08-16
WO2011045258A1 (en) 2011-04-21
US8841289B2 (en) 2014-09-23
JP2013507417A (ja) 2013-03-04

Similar Documents

Publication Publication Date Title
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BRPI0811280B8 (pt) compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos
IN2014DN03206A (https=)
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
BRPI1015568B8 (pt) derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica
ECSP099177A (es) Derivados de quinazolinona e isoquinolinona
ATE557015T1 (de) 3,4-diarylpyrazole als proteinkinaseinhibitoren
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
BRPI1011657A2 (pt) derivados aminopropiônicos substituídos como inibidores de neprilisina
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
SV2011003855A (es) Heteroarilos sustituidos
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
CL2012000708A1 (es) Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades.
MX2011009847A (es) Agentes antihelminticos y su uso.
MX367131B (es) Sales de xantilio 3,6-disustituidas.
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
MX2009013501A (es) Compuestos piperidinicos y sus usos.
BRPI0511874A (pt) derivados da pirrolopiridina
UY29301A1 (es) Derivados amida
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]